London, UK – Veritas, The Genome Company, recently made a significant impact at the Festival of Genomics, held from January 28-29 in London. As a leading event in the life sciences sector, the festival provided an exceptional platform for Veritas to showcase its expertise and connect with healthcare professionals, organizations, and the broader genomics community.

The Festival of Genomics, celebrating its 11th year as the UK’s largest life sciences event, draws over 8,000 attendees from more than 55 countries, featuring over 360 speakers and a vibrant exhibition floor.

Veritas was prominently present with a dedicated booth, where our team actively engaged with attendees, sharing insights into their cutting-edge products and services. Highlighted our specialized knowledge in critical areas of genomics, we demonstrated our commitment to advancing healthcare through precision medicine.

Our experts focused on several key areas:

• Pharmacogenomics: Providing insights into how an individual’s genetic makeup influences their response to drugs.
• Prenatal medicine: Discussing advancements in genetic testing and counseling for expectant parents.
• Polygenic risk scores: Explaining the utility of these scores in assessing an individual’s risk for common diseases.
• Genetic diagnosis: Showcasing their capabilities in identifying genetic causes of rare and inherited conditions.
• Whole genome and exome sequencing: Detailing the comprehensive genomic information obtained through these advanced sequencing technologies.

Beyond the valuable interactions at our booth, Veritas’s Medical Director, Dr. Luis Izquierdo, delivered a compelling presentation titled “Elective vs Reactive PGx: Optimizing Drug Therapy Through Pharmacogenomics.” His session highlighted that while drug prescriptions often assume uniform effectiveness, an individual’s genetics can significantly alter how they metabolize and react to medication, potentially leading to adverse reactions or reduced efficacy. Dr. Izquierdo emphasized how pharmacogenomics (PGx) aims to personalize medicine by identifying the right drug and dosage based on a patient’s genetic makeup, with studies showing that preemptive PGx testing can reduce adverse drug reactions and lead to cost savings. 

He further explained the two approaches: reactive pharmacogenomics, which involves testing after a patient experiences adverse effects or an unexpected response to a prescribed drug, and elective (or proactive) pharmacogenomics, which tests a patient’s genetic makeup before any drugs are prescribed to anticipate potential drug responses throughout their lifetime and guide personalized medication choices from the outset.

Veritas reinforced its position as a leader in the genomics field, dedicated to supporting healthcare professionals and organizations in leveraging genomic data for improved patient outcomes and population health initiatives. The company’s participation underscored its mission to make genomic information accessible and actionable, solidifying its role at the forefront of the genomics revolution.